EF Hutton Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for NRX Pharmaceuticals (NASDAQ:NRXP) and maintained a price target of $31.
October 30, 2024 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for NRX Pharmaceuticals and maintained a price target of $31, indicating confidence in the company's potential for growth.
The reaffirmation of a Buy rating and a $31 price target by EF Hutton suggests positive sentiment and confidence in NRX Pharmaceuticals' future performance. This could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100